Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tscan Therapeutics Inc
(NQ:
TCRX
)
5.670
-0.020 (-0.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tscan Therapeutics Inc
< Previous
1
2
3
Next >
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
November 02, 2023
Company to host virtual KOL event featuring Monzr M. Al Malki, M.D., on Monday, December 11, at 8:00 a.m. ET to discuss the data presented at the ASH Annual Meeting
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
September 27, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
September 05, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Inc. (NASDAQ: TCRX) Near the Top of Equities by Percentage Gain on 5/9
May 09, 2023
Via
Investor Brand Network
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
August 29, 2023
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Transition of Chief Financial Officer
June 29, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
June 06, 2023
TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on target...
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
June 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Closing of Public Offering
June 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Pricing of $140 Million Public Offering
May 26, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Launch of Proposed Public Offering
May 25, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
May 24, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 17, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease
May 09, 2023
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
May 09, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 02, 2023
Company to host a virtual event to discuss highlights from its Phase 1 umbrella trial of TSC-100 and TSC-101 on Wednesday, May 17, 2023, at 5:30 p.m. ET
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
April 10, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces CEO Transition
March 31, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
March 14, 2023
Patient treated with TSC-101, the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantation
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
March 13, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
March 08, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
February 21, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
January 23, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
January 05, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
December 12, 2022
Poster presents Phase 1 trial design and translational assays to generate early evidence of biological activity in residual leukemia after hematopoietic cell transplantation
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
December 01, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.